

# Jonathan Kay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6687996/publications.pdf>

Version: 2024-02-01

169  
papers

17,610  
citations

50276

46  
h-index

13379

130  
g-index

176  
all docs

176  
docs citations

176  
times ranked

17224  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 1385-1395.	1.9	10
2	The disease burden of axial spondyloarthritis: through a gendered lens. <i>Clinical Rheumatology</i> , 2022, 41, 1115-1124.	2.2	5
3	Development of a screening tool to identify patients with axial spondyloarthritis: a cognitive interview study. <i>Clinical Rheumatology</i> , 2022, , 1.	2.2	1
4	Development and testâ€“retest reliability of a screening tool for axial spondyloarthritis. <i>PLoS ONE</i> , 2022, 17, e0269494.	2.5	1
5	Healing of erosions in rheumatoid arthritis remains elusive: results with 24 months of the anabolic agent teriparatide. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 11-14.	1.1	3
6	Disease Burden and Health-Related Quality of Life Among Women and Men with Spondyloarthritis: An Exploratory Analysis of a Population-Based Sample. <i>Journal of Women's Health</i> , 2021, 30, 1637-1644.	3.3	1
7	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 727-738.	0.9	76
8	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. <i>Arthritis Research and Therapy</i> , 2021, 23, 51.	3.5	18
9	Pharmacokinetic equivalence of CTâ€“P17 to highâ€“concentration (100Âmg/ml) reference adalimumab: A randomized phase I study in healthy subjects. <i>Clinical and Translational Science</i> , 2021, 14, 1280-1291.	3.1	11
10	AB0198â€“...EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB) Tj ETQqO 0 0 rgBT <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1123-1124.	0.9	1
11	AB0892-HPRâ€“...PATIENT PERSPECTIVES ON PROVIDER PRACTICES LEADING TO AN AXIAL SPONDYLOARTHRITIS DIAGNOSIS: A QUALITATIVE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1469.2-1470.	0.9	0
12	Randomised, phase I pharmacokinetic study of adalimumab biosimilar CTâ€“P17 (40â€“mg/0.4â€“mL) by autoinjector and prefilled syringe in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4323-4333.	2.4	7
13	Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1015-1030.	2.3	9
14	POS1474-HPRâ€“...PERSONAL EXPERIENCES WITH DIAGNOSTIC DELAY AMONG AXIAL SPONDYLOARTHRITIS PATIENTS â€“ A QUALITATIVE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1022.2-1022.	0.9	0
15	Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0252018.	2.5	6
16	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 338-346.	0.6	3
17	Physical Activity and Attitudes Toward Exercise in People With Axial and Peripheral Spondyloarthritis. <i>Journal of Rheumatology</i> , 2021, 48, 513-519.	2.0	2
18	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 338-346.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Patient perspectives on health care provider practices leading to an axial spondyloarthritis diagnosis: an exploratory qualitative research study. BMC Family Practice, 2021, 22, 251.	2.9	5
20	Clinical trial and “real-world” data support switching from a bio-originator to its biosimilar. Annals of the Rheumatic Diseases, 2020, 79, e44-e44.	0.9	7
21	Hand Rheumatoid Arthritis. , 2020, , 179-184.		0
22	Overcoming barriers to biosimilars in inflammatory arthritis. Nature Reviews Rheumatology, 2020, 16, 65-66.	8.0	3
23	Physical activity and attitudes and perceptions towards physical activity in patients with spondyloarthritis: A systematic review. Seminars in Arthritis and Rheumatism, 2020, 50, 289-302.	3.4	6
24	Primary care physician perspectives on barriers to diagnosing axial Spondyloarthritis: a qualitative study. BMC Family Practice, 2020, 21, 204.	2.9	18
25	Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey. ACR Open Rheumatology, 2020, 2, 391-400.	2.1	12
26	A Time-Response Measure to Assess Clinical Equivalence in Rheumatoid Arthritis: An Assessment Using Data From Clinical Trials of Biosimilars. Statistics in Biopharmaceutical Research, 2020, , 1-13.	0.8	0
27	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open, 2020, 6, e001370.	3.8	23
28	Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis and Rheumatology, 2020, 72, 1067-1071.	5.6	13
29	Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?. BioDrugs, 2020, 34, 723-732.	4.6	18
30	Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms. Arthritis Care and Research, 2019, 71, 323-330.	3.4	25
31	Biosimilars in Dermatology: Analytical, Regulatory, and Clinical Considerations: A Treatise From the Medical Board of the National Psoriasis Foundation. Journal of Psoriasis and Psoriatic Arthritis, 2019, 4, 125-132.	0.7	1
32	The “Treat to Target” Approach to Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2019, 45, 487-504.	1.9	17
33	Are There Benefits and Risks to Biosimilars from a Patient Perspective?. Rheumatic Disease Clinics of North America, 2019, 45, 465-476.	1.9	5
34	A “wind of change” to biosimilars: The <sc>NOR</sc> “<sc>SWITCH</sc> trial and its extension. Journal of Internal Medicine, 2019, 285, 693-695.	6.0	3
35	A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 1101-1111.	5.6	71
36	PANLAR consensus statement on biosimilars. Clinical Rheumatology, 2019, 38, 1485-1496.	2.2	9

#	ARTICLE	IF	CITATIONS
37	SAT0162â€¦A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
38	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the Rheumatic Diseases, 2019, 78, 872-878.	0.9	36
39	Controversies in Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, xv-xvi.	1.9	0
40	Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2018, 47, 270-275.	1.1	2
41	The Science Behind Biosimilars. Arthritis and Rheumatology, 2018, 70, 334-344.	5.6	36
42	Reply. Arthritis and Rheumatology, 2018, 70, 476-476.	5.6	0
43	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Annals of the Rheumatic Diseases, 2018, 77, 165-174.	0.9	173
44	e48â€¦Effects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis. Rheumatology, 2018, 57, .	1.9	3
45	THU0184â€¦Impact of immunogenicity on clinical efficacy and administration related reaction in tn timers: a pooled-analysis from three biosimilar studies in patients with rheumatoid arthritis. , 2018, , .		0
46	Treat-to-target (T2T) recommendations for gout. Annals of the Rheumatic Diseases, 2017, 76, 632-638.	0.9	118
47	Biosimilars: implications for rheumatoid arthritis therapy. Current Opinion in Rheumatology, 2017, 29, 260-268.	4.3	22
48	Clinical trials of biosimilars should become more similar. Annals of the Rheumatic Diseases, 2017, 76, 4-6.	0.9	20
49	Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis and Rheumatology, 2017, 69, 1741-1750.	5.6	32
50	Biosimilar switching â€” â€œTo set a form upon desired changeâ€œ. Nature Reviews Rheumatology, 2017, 13, 391-392.	8.0	9
51	Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naïve patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Annals of the Rheumatic Diseases, 2017, 76, 1279-1284.	0.9	64
52	OP0203â€¦Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an) Tj ETQq0 0 0 rgBT /Overlock d0 Tf 50 13		
53	Gadolinium-Induced Fibrosis. Rare Diseases of the Immune System, 2017, , 209-237.	0.1	0
54	Biosimilars: New or DÃ©jÃ Vu?. Arthritis and Rheumatology, 2016, 68, n/a-n/a.	5.6	13

#	ARTICLE	IF	CITATIONS
55	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.9	160
56	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1081-1091.	0.9	152
57	Differential Expression of Hedgehog and Snail in Cutaneous Fibrosing Disorders. <i>American Journal of Clinical Pathology</i> , 2016, 146, 709-717.	0.7	13
58	Imaging for Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 695-710.	1.9	40
59	Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2016, 18, 72.	4.7	10
60	Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016, 43, 2120-2130.	2.0	33
61	THU0138â€¦Secondary Efficacy Results Up To Week 24 from A Phase III Study Comparing SB5 (An) Tj ETQq1 1 0.784314 rgBT /Overlo Rheumatoid Arthritis despite Methotrexate Therapy. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 231.1-231.	0.9	0
62	Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning. <i>Arthritis and Rheumatology</i> , 2016, 68, 332-336.	5.6	4
63	Efficacy and safety results from a Phase 3, randomized, placeboâ€œcontrolled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 1143-1156.	1.9	16
64	The term â€œnon-radiographic axial spondyloarthritisâ€™ is much more important to classify than to diagnose patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 791-794.	0.9	105
65	Gadolinium-Induced Fibrosis. <i>Annual Review of Medicine</i> , 2016, 67, 273-291.	12.2	66
66	SAT0151â€¦Safety Profile of BOW015, A Biosimilar Infliximab, In Healthy Subjects and Patients with Active Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 706.2-706.	0.9	1
67	Utilizing the METEOR initiative to improve rheumatoid arthritis patient care. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 425-431.	0.3	0
68	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 349-354.	0.9	7
69	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor Î± inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015, 17, 14.	3.5	49
70	Biosimilars in rheumatology: current perspectives and lessons learnt. <i>Nature Reviews Rheumatology</i> , 2015, 11, 713-724.	8.0	96
71	Biosimilars in rheumatology: what the clinician should know. <i>RMD Open</i> , 2015, 1, e000010-e000010.	3.8	39
72	Gadolinium-based compounds induce NLRP3-dependent IL-1Î² production and peritoneal inflammation. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2062-2069.	0.9	37

#	ARTICLE	IF	CITATIONS
73	Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 538-546.	0.9	75
74	Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1051-1057.	0.9	128
75	Miscellaneous arthropathies. , 2015, , 1420-1431.		0
76	Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. <i>Rheumatology</i> , 2014, 53, 1613-1617.	1.9	10
77	OP0012â€¦A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 64.1-64.	0.9	6
78	Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1811-1818.	0.9	29
79	Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. <i>Arthritis Research and Therapy</i> , 2014, 16, R40.	3.5	93
80	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 62-68.	0.9	659
81	Current status of nephrogenic systemic fibrosis. <i>Clinical Radiology</i> , 2014, 69, 661-668.	1.1	100
82	THU0444â€¦Assessment of Global Disease Activity in RA by Patients and Physicians: Cultural Differences across Countries in the Meteor Database. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 336.2-336.	0.9	1
83	Nephrogenic Systemic Fibrosis. , 2014, , 247-254.		1
84	Preface. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, xv-xvi.	1.9	0
85	<b>Rituximab biosimilars</b>. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1049-1062.	3.1	34
86	Relapsing Polychondritis. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 263-276.	1.9	45
87	Erosion defined: back to basics. <i>Nature Reviews Rheumatology</i> , 2013, 9, 323-324.	8.0	1
88	Biosimilars to treat inflammatory arthritis: the challenge of proving identity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1589-1593.	0.9	52
89	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Rheumatology</i> , 2013, 52, 1845-1855.	1.9	28
90	Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis. <i>Arthritis Care and Research</i> , 2013, 65, 637-642.	3.4	2

#	ARTICLE	IF	CITATIONS
91	Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Rheumatology</i> , 2013, 52, 560-567.	1.9	22
92	FRI0096â€¦Haq baseline values in an international registry of ra patients during the era of biologic therapies: the 2013 meteor database.. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A402.1-A402.	0.9	0
93	THU0202â€¦Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A232.1-A232.	0.9	3
94	Fibrosis-Associated Single-Nucleotide Polymorphisms in TGFB1 and CAV1 Are Not Associated With the Development of Nephrogenic Systemic Fibrosis. <i>American Journal of Dermatopathology</i> , 2013, 35, 351-356.	0.6	4
95	FRI0211â€¦Safety and efficacy of subcutaneous golimumab in chinese patients with active rheumatoid arthritis despite mtx therapy: results from a randomized, placebo-controlled, phase 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A444.2-A444.	0.9	4
96	Sensorineural Hearing Loss following Imatinib (Gleevec) Administration. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 146, 335-337.	1.9	14
97	ACR/EULAR 2010 rheumatoid arthritis classification criteria. <i>Rheumatology</i> , 2012, 51, vi5-vi9.	1.9	353
98	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1671-1679.	0.9	53
99	Evolution of treatment for rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, vi28-vi36.	1.9	139
100	Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 489-503.	3.3	76
101	Health Canada/BIOTEC Canada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. <i>Biologicals</i> , 2012, 40, 517-527.	1.4	17
102	The advent of biosimilar therapies in rheumatologyâ€”â€œO Brave New Worldâ€•. <i>Nature Reviews Rheumatology</i> , 2012, 8, 430-436.	8.0	97
103	Biosimilars: a regulatory perspective from America. <i>Arthritis Research and Therapy</i> , 2011, 13, 112.	3.5	49
104	Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: AÂˆdiagnostic aid. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 741-747.	1.2	13
105	Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 1095-1106.e7.	1.2	163
106	Assessment of control of rheumatoid arthritis disease activity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 497-507.	3.3	20
107	Treating rheumatoid arthritis to target: an international initiative. <i>Current Reviews in Musculoskeletal Medicine</i> , 2011, 4, 79-83.	3.5	0
108	Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: Risk reduction in a chronic inflammatory disease. <i>Arthritis Care and Research</i> , 2011, 63, 512-521.	3.4	76



#	ARTICLE	IF	CITATIONS
109	Incidence of Nephrogenic Systemic Fibrosis after Adoption of Restrictive Gadolinium-based Contrast Agent Guidelines. Radiology, 2011, 260, 105-111.	7.3	134
110	Golimumab: A novel human anti-TNF- $\alpha$ monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evidence, 2010, 4, 159.	4.7	27
111	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis and Rheumatism, 2010, 62, 2582-2591.	6.7	246
112	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 2010, 62, 2569-2581.	6.7	6,781
113	Gadolinium and systemic fibrosis: guilt by association. Annals of the Rheumatic Diseases, 2010, 69, 1895-1897.	0.9	15
114	Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention. Rheumatic Disease Clinics of North America, 2010, 36, 385-404.	1.9	169
115	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. Annals of the Rheumatic Diseases, 2010, 69, 1589-1595.	0.9	152
116	Rheumatic Manifestations of Diabetes Mellitus. Rheumatic Disease Clinics of North America, 2010, 36, 681-699.	1.9	88
117	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2010, 69, 1580-1588.	0.9	2,994
118	Nephrogenic Systemic Fibrosis after Gadopentetate Dimeglumine Exposure: Case Series of 36 Patients. Radiology, 2009, 253, 81-89.	7.3	95
119	E-selectin, Interleukin 18, Serum Amyloid A, and Matrix Metalloproteinase 9 Are Associated with Clinical Response to Golimumab plus Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Journal of Rheumatology, 2009, 36, 1371-1379.	2.0	30
120	Case 37-2009. New England Journal of Medicine, 2009, 361, 2166-2176.	27.0	11
121	CMR2009: 5.04: Post-mortem analysis of gadolinium distribution in NSF subjects. Contrast Media and Molecular Imaging, 2009, 4, 274-274.	0.8	1
122	Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. Journal of Magnetic Resonance Imaging, 2009, 30, 1335-1340.	3.4	36
123	Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator. Arthritis and Rheumatism, 2009, 61, 495-500.	6.7	13
124	A rheumatology-specific informatics-based application with a disease activity calculator. Arthritis and Rheumatism, 2009, 61, 488-494.	6.7	13
125	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor $\pm$ inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet, The, 2009, 374, 210-221.	13.7	497
126	Methotrexate: the gold standard without standardisation. Annals of the Rheumatic Diseases, 2009, 68, 1081-1082.	0.9	15



#	ARTICLE	IF	CITATIONS
127	Nephrogenic Systemic Fibrosis: A Pathologic Study of Autopsy Cases. Archives of Pathology and Laboratory Medicine, 2009, 133, 1943-1948.	2.5	34
128	Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Current Rheumatology Reports, 2008, 10, 195-204.	4.7	29
129	Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. Current Rheumatology Reports, 2008, 10, 235-248.	4.7	13
130	What Causes Nephrogenic Systemic Fibrosis?. Dialysis and Transplantation, 2008, 37, 95-98.	0.2	2
131	Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis and Rheumatism, 2008, 58, 964-975.	6.7	266
132	Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis and Rheumatism, 2008, 58, 2543-2548.	6.7	148
133	Case 6-2008. New England Journal of Medicine, 2008, 358, 827-838.	27.0	57
134	Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Annals of the Rheumatic Diseases, 2008, 67, iii66-iii69.	0.9	33
135	Nephrogenic systemic fibrosis: a new concern for rheumatologists. Nature Clinical Practice Rheumatology, 2008, 4, 445-445.	3.2	0
136	Gadolinium and nephrogenic systemic fibrosis: The evidence of things not seen. Cleveland Clinic Journal of Medicine, 2008, 75, 112-117.	1.3	11
137	Cutaneous changes of nephrogenic systemic fibrosis: Predictor of early mortality and association with gadolinium exposure. Arthritis and Rheumatism, 2007, 56, 3433-3441.	6.7	196
138	Wegener's granulomatosis: Is biologic therapy useful?. Current Rheumatology Reports, 2006, 8, 303-311.	4.7	6
139	Case 39-2006. New England Journal of Medicine, 2006, 355, 2678-2689.	27.0	22
140	Case 4-2006. New England Journal of Medicine, 2006, 354, 623-630.	27.0	9
141	Case 31-2005. New England Journal of Medicine, 2005, 353, 1605-1613.	27.0	16
142	Nephrogenic Fibrosing Dermopathy: A Review of the Massachusetts General Hospital Experience. Journal of Cutaneous Pathology, 2005, 32, 89-89.	1.3	0
143	Case 35-2004. New England Journal of Medicine, 2004, 351, 2219-2227.	27.0	42
144	The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. British Journal of Rheumatology, 2004, 43, iii2-iii9.	2.3	188

#	ARTICLE	IF	CITATIONS
145	Advanced glycation endproducts and osteoarthritis. Current Rheumatology Reports, 2003, 5, 33-40.	4.7	60
146	Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood, 2002, 99, 2259-2261.	1.4	68
147	Î²2-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney International, 2001, 59, 990-1002.	5.2	71
148	FR10002â€¦IL-1 receptor antagonist (il-1ra) treatment is associated with improvement of anaemia in rheumatoid arthritis. , 2001, , .		0
149	The Association of Relapsing Polychondritis and Myelodysplastic Syndrome: Report of Three Cases. Journal of Clinical Rheumatology, 2000, 6, 146-149.	0.9	12
150	Osteoarticular disorders of renal origin: disease-related and iatrogenic. Best Practice and Research in Clinical Rheumatology, 2000, 14, 285-305.	3.3	29
151	Beta2-microglobulin amyloidosis in renal failure: Understanding this recently recognized condition. Cleveland Clinic Journal of Medicine, 1999, 66, 145-147.	1.3	6
152	Î²2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney International, 1998, 53, 1365-1373.	5.2	85
153	Development of Gastrointestinal Î²2-Microglobulin Amyloidosis Correlates With Time on Dialysis. American Journal of Surgical Pathology, 1998, 22, 729-735.	3.7	36
154	Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin.. Journal of the American Society of Nephrology: JASN, 1998, 9, 277-283.	6.1	22
155	Î²2-microglobulin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1997, 4, 187-211.	3.0	11
156	Interaction between Î²2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney International, 1997, 51, 1514-1519.	5.2	58
157	Performance characteristics of a dialysis-related amyloidosis questionnaire.. Journal of the American Society of Nephrology: JASN, 1996, 7, 1235-1240.	6.1	8
158	Shoulder Pain in the Dialysis Patient. Seminars in Dialysis, 1995, 8, 105-121.	1.3	0
159	Enhancement of human monocyte beta-glucan receptors by glucocorticoids. Immunology, 1994, 81, 96-102.	4.4	16
160	Vascular Occlusion and Cardiac Conduction Disturbances in a Patient Undergoing Peritoneal Dialysis. Seminars in Dialysis, 1993, 6, 135-139.	1.3	2
161	Lyme disease. Comprehensive Therapy, 1993, 19, 157-62.	0.2	0
162	Musculoskeletal manifestations in Î²2 -microglobulin amyloidosis. Case discussion. Arthritis and Rheumatism, 1992, 35, 592-602.	6.7	14

#	ARTICLE	IF	CITATIONS
163	Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis and Rheumatism, 1992, 35, 926-932.	6.7	47
164	Identification and characterization of opsonic fibronectin in synovial fluids of patients with active rheumatoid arthritis. Arthritis and Rheumatism, 1991, 34, 687-696.	6.7	5
165	Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes.. Journal of Experimental Medicine, 1991, 173, 1511-1520.	8.5	174
166	Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex.. Journal of Experimental Medicine, 1989, 170, 1133-1148.	8.5	298
167	Anesthesia for Open Lung Biopsy in a Patient with Intracardiac Tumor. Anesthesiology, 1989, 71, 607-610.	2.5	2
168	Synovial fluid eosinophilia in lyme disease. Arthritis and Rheumatism, 1988, 31, 1384-1389.	6.7	25
169	Separation of functionally distinct subpopulations of Corynebacterium parvum-activated macrophages with predominantly stimulatory or suppressive effect on the cell-mediated cytotoxic T cell response. Cellular Immunology, 1979, 42, 28-41.	3.0	37